Hikma (HIK) and Vectura's (VEC) joint effort to launch the first unbranded version of GlaxoSmithKline's (GSK) top-selling asthma drug, Advair, has hit a roadblock. The two companies - which filed their drug with the US Food and Drug Administration (FDA) in 2016 - have had their initial application rejected, meaning they no longer expect to launch this year.
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis